Cargando…

A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India

INTRODUCTION: Limited treatment options exist for COVID-19 infections; thus, attempts from complementary and alternative systems (CAM) of medicine are being explored as possible therapeutic options. Ayurcov is a formulation made of ingredients mentioned in Ayurveda. These constituents have proven an...

Descripción completa

Detalles Bibliográficos
Autores principales: Sankhe, Ajay Prabhakar, Memane, Nanasaheb Somnath, Gawali, Vijaykumar P., Memane, Sonal Nanasaheb, Ramakrishnan, Ganesh, Kundu, Tapanendu, Bagul, Mayur Nimba, Kumar, Ashotosh, Bansal, Vikram, Tiwari, Rashmi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949691/
https://www.ncbi.nlm.nih.gov/pubmed/35341943
http://dx.doi.org/10.1016/j.ctim.2022.102824
_version_ 1784674965573861376
author Sankhe, Ajay Prabhakar
Memane, Nanasaheb Somnath
Gawali, Vijaykumar P.
Memane, Sonal Nanasaheb
Ramakrishnan, Ganesh
Kundu, Tapanendu
Bagul, Mayur Nimba
Kumar, Ashotosh
Bansal, Vikram
Tiwari, Rashmi
author_facet Sankhe, Ajay Prabhakar
Memane, Nanasaheb Somnath
Gawali, Vijaykumar P.
Memane, Sonal Nanasaheb
Ramakrishnan, Ganesh
Kundu, Tapanendu
Bagul, Mayur Nimba
Kumar, Ashotosh
Bansal, Vikram
Tiwari, Rashmi
author_sort Sankhe, Ajay Prabhakar
collection PubMed
description INTRODUCTION: Limited treatment options exist for COVID-19 infections; thus, attempts from complementary and alternative systems (CAM) of medicine are being explored as possible therapeutic options. Ayurcov is a formulation made of ingredients mentioned in Ayurveda. These constituents have proven antiviral, detoxifying, immune-modulating, and bio-enhancing properties. The present study was carried out to evaluate the therapeutic effect and safety of Ayurcov in patients with various severity states of COVID-19 infections. METHODS: A randomized, single blinded, controlled trial was carried out in adults diagnosed with mild-to-moderate, and severe COVID-19 infections confirmed by real time reverse transcriptase polymerase chain reaction (rRTPCR) test. The interventional group received three doses of ‘Ayurcov’. It is constituted of Haridra Churna (Curcuma longa), Go ark (Bos Indicus Distilled Urine), Sphatika (Alum), Sita (Rock Candy), Godugdham (Bos Indicus Milk) milk, Goghritam (Bos Indicus ghee) on Day 1, as an adjuvant to the standard of care, and the control group received only the standard of care. Key outcomes included: proportion of patients and time taken for symptom resolution, reduction in the rRT-PCR Ct values, safety, and functional status until 42 days after discharge. RESULTS: Ninety patients with mild-to-moderate and 30 patients with severe COVID-19 disease were recruited. It was observed that significantly more proportions of patients receiving Ayurcov had symptom relief much earlier than control group. Additionally, the interventional group showed significantly lower rRT-PCR Ct values. However, a shorter time of resolution of symptoms was observed with the interventional group in the mild to moderate category but not with those having severe symptoms. Similarly, a significantly better functional status was observed with interventional group on days 7 and 28 after discharge. Ayurcov was not observed with higher risks of any adverse/serious adverse events. CONCLUSIONS: Ayurcov as adjuvant with standard of care was associated with significantly earlier resolution of COVID-19 related symptoms than standard of care alone.
format Online
Article
Text
id pubmed-8949691
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-89496912022-03-25 A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India Sankhe, Ajay Prabhakar Memane, Nanasaheb Somnath Gawali, Vijaykumar P. Memane, Sonal Nanasaheb Ramakrishnan, Ganesh Kundu, Tapanendu Bagul, Mayur Nimba Kumar, Ashotosh Bansal, Vikram Tiwari, Rashmi Complement Ther Med Article INTRODUCTION: Limited treatment options exist for COVID-19 infections; thus, attempts from complementary and alternative systems (CAM) of medicine are being explored as possible therapeutic options. Ayurcov is a formulation made of ingredients mentioned in Ayurveda. These constituents have proven antiviral, detoxifying, immune-modulating, and bio-enhancing properties. The present study was carried out to evaluate the therapeutic effect and safety of Ayurcov in patients with various severity states of COVID-19 infections. METHODS: A randomized, single blinded, controlled trial was carried out in adults diagnosed with mild-to-moderate, and severe COVID-19 infections confirmed by real time reverse transcriptase polymerase chain reaction (rRTPCR) test. The interventional group received three doses of ‘Ayurcov’. It is constituted of Haridra Churna (Curcuma longa), Go ark (Bos Indicus Distilled Urine), Sphatika (Alum), Sita (Rock Candy), Godugdham (Bos Indicus Milk) milk, Goghritam (Bos Indicus ghee) on Day 1, as an adjuvant to the standard of care, and the control group received only the standard of care. Key outcomes included: proportion of patients and time taken for symptom resolution, reduction in the rRT-PCR Ct values, safety, and functional status until 42 days after discharge. RESULTS: Ninety patients with mild-to-moderate and 30 patients with severe COVID-19 disease were recruited. It was observed that significantly more proportions of patients receiving Ayurcov had symptom relief much earlier than control group. Additionally, the interventional group showed significantly lower rRT-PCR Ct values. However, a shorter time of resolution of symptoms was observed with the interventional group in the mild to moderate category but not with those having severe symptoms. Similarly, a significantly better functional status was observed with interventional group on days 7 and 28 after discharge. Ayurcov was not observed with higher risks of any adverse/serious adverse events. CONCLUSIONS: Ayurcov as adjuvant with standard of care was associated with significantly earlier resolution of COVID-19 related symptoms than standard of care alone. Published by Elsevier Ltd. 2022-08 2022-03-25 /pmc/articles/PMC8949691/ /pubmed/35341943 http://dx.doi.org/10.1016/j.ctim.2022.102824 Text en © 2022 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Sankhe, Ajay Prabhakar
Memane, Nanasaheb Somnath
Gawali, Vijaykumar P.
Memane, Sonal Nanasaheb
Ramakrishnan, Ganesh
Kundu, Tapanendu
Bagul, Mayur Nimba
Kumar, Ashotosh
Bansal, Vikram
Tiwari, Rashmi
A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India
title A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India
title_full A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India
title_fullStr A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India
title_full_unstemmed A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India
title_short A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India
title_sort randomized, controlled, blinded, parallel group, clinical trial to study the role of ayurcov (ayurcoro3), one day regimen as an adjuvant therapy for covid-19 disease management, at dedicated covid hospital (dch) in india
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949691/
https://www.ncbi.nlm.nih.gov/pubmed/35341943
http://dx.doi.org/10.1016/j.ctim.2022.102824
work_keys_str_mv AT sankheajayprabhakar arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia
AT memanenanasahebsomnath arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia
AT gawalivijaykumarp arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia
AT memanesonalnanasaheb arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia
AT ramakrishnanganesh arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia
AT kundutapanendu arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia
AT bagulmayurnimba arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia
AT kumarashotosh arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia
AT bansalvikram arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia
AT tiwarirashmi arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia
AT sankheajayprabhakar randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia
AT memanenanasahebsomnath randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia
AT gawalivijaykumarp randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia
AT memanesonalnanasaheb randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia
AT ramakrishnanganesh randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia
AT kundutapanendu randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia
AT bagulmayurnimba randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia
AT kumarashotosh randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia
AT bansalvikram randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia
AT tiwarirashmi randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia